Doctronic Inc.

Doctronic Inc. is an innovative provider of AI-driven telehealth services, facilitating remote medical consultations through an AI doctor that enhances the efficiency of healthcare delivery. Founded in 2024 by co-CEO Matt Pavelle and Adam Oskowitz and based in New York, US, Doctronic Inc. focuses on AI-driven telehealth solutions.

The company successfully completed its Seed funding round. In March 2026, Doctronic Inc. raised USD 40 million in series B funding co-led by Abstract and Lightspeed Venture Partners, with participation from Seven Stars, Union Square Ventures, Tusk Ventures, and Mantis. The founder has a history of entrepreneurship, although specific details about previous ventures are not available.

Doctronic specializes in providing AI-driven telehealth services through its core product, an AI doctor designed to assist human physicians in delivering medical consultations. The platform enables users to engage in video consultations with licensed healthcare professionals across all 50 states in the U. S. Notably, the AI doctor conducts initial assessments that prepare practitioners for more effective patient interactions during video visits.

The service aims to address various healthcare needs, such as consultations, prescriptions, referrals, and treatment plans, all conducted in a HIPAA-compliant and anonymous environment. Doctronic's client base primarily consists of individuals seeking immediate access to medical care without the need for insurance or in-person visits, effectively targeting users across diverse demographics and geographical markets, including urban and suburban areas throughout the United States. Revenue generation for Doctronic is facilitated through a straightforward transaction model primarily based on individual consultations. Customers pay for 15-minute consultations with licensed doctors, with no hidden costs involved.

Upon selecting a consultation time, users are required to provide their details and payment information. The structure is designed for direct-to-consumer transactions, allowing individuals to book appointments as needed, with the option to receive post-consultation notes and recommendations through the platform. While specific pricing plans for consultations are not detailed, the ease of access and the ability to consult top licensed doctors at any time contribute to the service's attractiveness and utility in the competitive telehealth market. The company plans to utilize the March 2026 funding to expand its AI doctor platform into pediatrics and strengthen partnerships with academic institutions, payers, digital health platforms, and hospital systems.